SCHEMBL3766072

SCHEMBL3766072

CC1(C)CC(=O)c2sc(N3CCOCC3)c(-c3ccnc(-c4cccc(Br)c4)n3)c2C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 1/20 0.39
PIK3CA P42336 10/20 0.39
PIK3CD O00329 7/20 0.39
PIK3CB P42338 7/20 0.39
PIK3CG P48736 7/20 0.39
ADK P55263 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
CASP1 P29466 1/20 0.36
BLM P54132 1/20 0.36
CASP7 P55210 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3766006 0.90 PIK3CA (0.43) PIK3CAPIK3CDPIK3CBPIK3CGALDH1A1
SCHEMBL3754750 0.86 HTR1A (0.38) PIK3CAPIK3CDPIK3CBPIK3CGBUB1
SCHEMBL3762227 0.82 PIK3CA (0.39) PIK3CAPIK3CDPIK3CBPIK3CGKDM4E
SCHEMBL3760142 0.81 PIK3CA (0.45) PRKDCPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL3764482 0.79 BUB1 (0.44) PIK3CAPIK3CDPIK3CBPIK3CGKDM4E
SCHEMBL3761577 0.78 PRKDC (0.42) PRKDCPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL3757579 0.78 PIK3CD (0.37) PIK3CAPIK3CDPIK3CBPIK3CGTDP1
SCHEMBL3762759 0.78 PRKDC (0.40) PRKDCPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL3766682 0.78 KDM1A (0.40) PIK3CAPIK3CDPIK3CBPIK3CGBUB1
SCHEMBL3762158 0.78 LRRK2 (0.38) PIK3CAPIK3CDPIK3CBPIK3CGKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA PRKDC 112/4885PIK3CA 3/4885PIK3CD 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.